<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mucopolysaccharidoses: Complications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mucopolysaccharidoses: Complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mucopolysaccharidoses: Complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 04, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs), also known as mucopolysaccharides. These conditions are differentiated by their clinical features and age of presentation  (<a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">table 1</a>). The MPS can affect many different systems, including the respiratory, cardiovascular, skeletal, and neurologic systems  (<a class="graphic graphic_table graphicRef120535" href="/z/d/graphic/120535.html" rel="external">table 2</a>). Enzyme replacement therapy (ERT) is available for some MPS. Other therapies focus on treatment of symptoms.</p><p>The complications associated with the MPS and their management are reviewed here. The clinical features, diagnosis, and treatment of these disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RESPIRATORY COMPLICATIONS</span><span class="headingEndMark"> — </span>Respiratory complications affect patients with all types of MPS and contribute to death and disability as their disease progresses. Respiratory abnormalities result from airway obstruction, excessive secretions, skeletal restriction, organomegaly, frequent infections, and neurologic compromise [<a href="#rid1">1-3</a>]. These problems can lead to progressive respiratory insufficiency, severe obstructive sleep apnea, and sudden death from central apnea.</p><p class="headingAnchor" id="H3"><span class="h2">Central apnea from cord compression</span><span class="headingEndMark"> — </span>MPS IV A and IV B patients are especially prone to high cord compression due to atlantoaxial instability and odontoid dysplasia, although this complication also occurs in other types. This condition may result in depressed respiration or sudden respiratory arrest [<a href="#rid4">4-7</a>]. Early cervical fusion is recommended in MPS IV patients and in other patients with cervical instability. (See <a class="local">'C1-C2 subluxation'</a> below and <a class="local">'Odontoid hypoplasia'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Airway obstruction</span><span class="headingEndMark"> — </span>Patients with MPS I, II, VI, and VII often develop upper airway obstruction due to an enlarged tongue, thickened gums, and engorged soft tissues of the nasopharynx [<a href="#rid1">1-3,8-11</a>]. Increased tonsillar and adenoid size due to storage of glycosaminoglycans (GAGs) in lymphatic tissue also contributes to obstruction. Upper airway obstruction may be exacerbated in certain positions (eg, raising the arms may result in obstruction of the thoracic inlet, causing facial plethora, distension of the neck veins, and shortness of breath) [<a href="#rid12">12</a>]. Airway problems may be worsened by excessive thick secretions due to chronic or recurrent ear and sinus infections. Progressive obstruction can result in sleep apnea with severe hypoxemia and right heart failure [<a href="#rid1">1,2,13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/6347.html" rel="external">"Mechanisms and predisposing factors for sleep-related breathing disorders in children"</a> and  <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p>Tracheal or lower airway obstruction can result from malformed and floppy tracheal cartilage, redundant respiratory epithelium, or pedunculated nodules [<a href="#rid10">10,15-17</a>]. Wheezing due to narrowed airways from increased mucus production and airway inflammation is common. In the setting of airway compromise, minor upper respiratory infections or pneumonia can cause severe reactive airway disease and airway edema. In patients with advanced disease, this may lead to sudden respiratory arrest [<a href="#rid1">1</a>]. (See <a class="local">'Pulmonary function abnormalities'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h3">Interventions</span><span class="headingEndMark"> — </span>Interventions are primarily directed at maintaining a stable airway. Removal of the tonsils and adenoids can temporarily reduce airway obstruction and sleep apnea, but these problems often recur [<a href="#rid8">8,13,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/97855.html" rel="external">"Adenotonsillectomy for obstructive sleep apnea in children", section on 'High-risk populations'</a>.)</p><p>Upper airway obstruction, especially when associated with sleep apnea, may be improved by continuous positive airway pressure (CPAP) applied at night [<a href="#rid8">8</a>]. Younger patients seem to adapt better to CPAP than older ones. However, facial dysmorphism may make it difficult to achieve the proper fit of masks. Bilevel positive airway pressure ventilators (BiPAP devices), which decrease pressure during exhalation and increase pressure during inhalation, may be better tolerated by some patients. (See  <a class="medical medical_review" href="/z/d/html/97854.html" rel="external">"Continuous positive airway pressure (CPAP) for pediatric obstructive sleep apnea"</a>.)</p><p>Supplemental oxygen at low flow rates can be used to treat arterial desaturation during sleep. However, oxygen therapy should be used with caution to avoid suppressing hypoxic respiratory drive. Patients with severe hypoxemia, hypercapnia, and sleep disturbance may require tracheotomy. Tracheotomy or tracheal T tubes are options in patients with signs of right heart failure and severe sleep apnea that cannot be improved with BiPAP or who have critical airway stenosis. If surgery or airway support with BiPAP is not possible, palliative care is given. (See  <a class="medical medical_review" href="/z/d/html/97855.html" rel="external">"Adenotonsillectomy for obstructive sleep apnea in children", section on 'Adjuvant surgical procedures'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Anesthesia</span><span class="headingEndMark"> — </span>Patients with MPS often have complications during general anesthesia. These are primarily due to the presence of airway obstruction, excessive secretions, a large tongue, and abnormal airway anatomy, resulting in extreme difficulty in endotracheal intubation [<a href="#rid10">10,19-24</a>]. Older patients or those with sleep apnea or other signs of airway obstruction are at increased risk for difficult intubation. (See  <a class="medical medical_review" href="/z/d/html/6391.html" rel="external">"The difficult pediatric airway for emergency medicine"</a>.)</p><p>In one report in 30 MPS patients who were anesthetized 141 times, preoperative signs of airway obstruction were present more often in patients with moderate to severe postoperative airway complications compared with those with mild or no complications (78 versus 23 percent) [<a href="#rid10">10</a>]. Extension of the neck may cause spinal cord injury due to instability of the cervical spine, increasing the difficulty of intubation [<a href="#rid5">5,25</a>].</p><p>These problems should be weighed carefully in making decisions about surgical procedures. Anesthesia should be administered at centers experienced in the management of MPS patients. A comprehensive plan should be made before performing general anesthesia, including management options if complications develop. Local or regional anesthesia should be used whenever possible [<a href="#rid10">10,19,20,24,26,27</a>].</p><p>If general anesthesia is unavoidable, fiberoptic intubation with an endotracheal tube smaller than indicated by the patient's age or weight may help with airway management [<a href="#rid10">10,28</a>]. Attempts to intubate without adequate visualization can lead to injury of the laryngeal tissue and airway edema.</p><p>Extubation may also be difficult in MPS patients. Glucocorticoids or other medications may be needed to reduce airway edema. In general though, earlier extubation is recommended if at all possible.</p><p class="headingAnchor" id="H7"><span class="h2">Sinopulmonary infections</span><span class="headingEndMark"> — </span>MPS patients have frequent or chronic pulmonary infections, otitis media, and sinusitis in the first few years after birth [<a href="#rid1">1,3,8,13,18</a>]. The associated thick and copious secretions can worsen airway obstruction. Minor respiratory infections often progress to pneumonia with consolidation and require hospitalization.</p><p>Obstruction of the Eustachian tubes and sinus ostia contribute to the persistence of infections. Another possible mechanism for increased infection is abnormal immune function. T cell proliferative response and antibody production were decreased in a murine model of MPS VII after antigen challenge, and a quantitative defect in natural killer (NK) and B cells with normal immunoglobulin levels and function was identified in a family with MPS II [<a href="#rid29">29,30</a>].</p><p>The antimicrobial management of infections is similar to those without associated MPS. However, recovery time may be longer for MPS patients, and bronchodilators may be needed to treat reactive airway disease. Otitis media may also be more difficult to treat, and tympanostomy tubes may be required. Tube placement should be considered more readily than in patients without MPS. (See  <a class="medical medical_review" href="/z/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment", section on 'Initial antibiotic therapy'</a>.)</p><p>Preventive measures include influenza vaccine in addition to standard childhood immunizations. Prophylactic antibiotic treatment has been used, especially during the winter, and nebulized <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> has been used for prophylaxis in patients with tracheotomies. However, the efficacy of these approaches in MPS is unknown. (See  <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a> and  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'</a>.)</p><p class="headingAnchor" id="H13850017"><span class="h2">Pulmonary function abnormalities</span><span class="headingEndMark"> — </span>Patients with MPS also have pulmonary function abnormalities that can be multifactorial [<a href="#rid31">31</a>]. They are a clinically important cause of morbidity and mortality. However, many MPS patients have trouble performing traditional pulmonary function testing to the standard guidelines because they cannot blow out sufficiently for long periods of time, making assessment difficult.</p><p>The restrictive disease is most likely related to their skeletal abnormalities and enlarged liver and spleen and not to interstitial disease. Although obstructive disease may be less important, it is not uncommon for these patients to be treated with bronchodilators as part of their general care.</p><p>In one series of 35 patients with MPS I, II, IV A, or VI, 48 percent had restrictive lung disease based upon spirometry, and 9 percent had obstructive lung disease [<a href="#rid32">32</a>]. In another series, 12 of 15 patients with MPS II had a mean forced expiratory volume in 1 second (FEV<sub>1</sub>) below 80 percent predicted [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CARDIAC COMPLICATIONS</span><span class="headingEndMark"> — </span>Cardiac abnormalities may result from the underlying MPS disorder or as a complication of severe pulmonary disease and associated chronic hypoxemia [<a href="#rid34">34</a>]. Cardiomyopathy and endocardial fibroelastosis occur rarely in young, severely affected patients with Hurler syndrome (MPS I) and MPS VI [<a href="#rid35">35-37</a>]. Cardiac problems may be complicated by coronary artery and other vascular diseases. (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Valvular disease</span><span class="headingEndMark"> — </span>Progressive thickening of the mitral and aortic valves causing insufficiency occurs often in MPS, especially in types I, II, and VI, and less commonly in MPS III A to D [<a href="#rid2">2,8,38</a>]. In one series of 84 MPS patients, mitral and aortic regurgitation were detected in 64 and 41 percent, respectively [<a href="#rid39">39</a>]. Tricuspid and pulmonic valve regurgitation also occur and may be exacerbated by pulmonary hypertension. (See  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/5778.html" rel="external">"Aortic regurgitation in children"</a>.)</p><p>Although regurgitation can be detected in young patients, progressive worsening of valvular competence typically results in heart failure in late school age or in the teens [<a href="#rid1">1,39,40</a>]. Severely affected patients may require valve replacement [<a href="#rid41">41-43</a>].</p><p>In patients with valvular insufficiency, systemic hypertension due to aortic coarctation and other vascular diseases can result in further compromise and should be treated [<a href="#rid44">44</a>]. It is uncertain whether prophylactic afterload reduction is beneficial in patients with moderate regurgitation and without hypertension. This approach has been used successfully to treat the cardiovascular manifestations of Marfan syndrome. (See  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Vascular disease</span><span class="headingEndMark"> — </span>Storage cells accumulate in the walls of arterial blood vessels, including the coronary arteries, leading to impaired flow and ischemia [<a href="#rid45">45,46</a>]. The coronary lesions involve the entire course of the vessels. Obstruction may result in sudden death [<a href="#rid45">45</a>]. Vigilance is required to detect coronary disease as it is usually unexpected in young children. Furthermore, the clinical presentation may not be typical, and coronary angiography may not predict the severity of the disease [<a href="#rid45">45</a>].</p><p>Intimal lesions can result in narrowing of the abdominal aorta, causing hypertension and poor perfusion of the lower extremities [<a href="#rid44">44</a>]. Arteriopathy also affects other vessels, including the renal, mesenteric, and iliac arteries. Narrowing can be detected by arteriography, ultrasound, and magnetic resonance imaging (MRI).</p><p class="headingAnchor" id="H11"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Chronic hypoxemia due to airway obstruction and pulmonary disease can lead to pulmonary hypertension [<a href="#rid1">1,10</a>]. Pulmonary hypertension may exacerbate right heart failure caused by mitral valve regurgitation. Therapy should be directed at maintaining a secure airway and avoiding hypoxemia, especially during the night. (See  <a class="medical medical_review" href="/z/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/109342.html" rel="external">"Pulmonary hypertension in children: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H2474401791"><span class="h2">Myocardial infarction and stroke</span><span class="headingEndMark"> — </span>Later complications in adults include myocardial infarction and stroke [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H12"><span class="h1">SKELETAL AND CONNECTIVE TISSUE COMPLICATIONS</span><span class="headingEndMark"> — </span>Storage material in cells that form the connective tissues leads to abnormalities in bone, joints, and ligaments. These problems interfere with growth, cause dysmorphism, impair mobility, and cause pain.</p><p class="headingAnchor" id="H13"><span class="h2">Dysostosis multiplex</span><span class="headingEndMark"> — </span>The constellation of characteristic bony abnormalities is known as dysostosis multiplex. This condition occurs in MPS I, II, IV, VI, and VII and is less extensive in MPS III and attenuated variants [<a href="#rid2">2,8,48</a>]. The radiographic findings of dysostosis multiplex are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis", section on 'Radiologic findings'</a>.)</p><p>The bone disease in Morquio patients (MPS IV A and IV B) begins with ovoid vertebrae and typical features of dysostosis multiplex and progresses with age to appear similar to spondyloepiphyseal dysplasia [<a href="#rid49">49</a>]. The ovoid vertebrae flatten and collapse, resulting in distinctive platyspondyly (thin, flat vertebral bodies). Patients can also have beaking of the anterior margin (central for MPS IV and lower third for MPS I) of the lumbar vertebrae.</p><p>Abnormalities of the vertebral bodies can result in spinal instability and kyphoscoliosis and lead to neurologic deficits. Circumferential arthrodesis is the preferred approach to severe thoracolumbar kyphoscoliosis [<a href="#rid50">50</a>]. Early <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fmedicine-and-dentistry%2Fspinal-cord-decompression&amp;token=XrU5Y3rS9tHE4eceRL%2BIpcrz8lhEWt%2B6Ymy2UBKy8vo38LskxTijX9NAIM48vCjOCuqqIy5UmjJMM5V8kLGO%2F28lYgf7LpaR3J5cio21D2o%3D&amp;TOPIC_ID=2932" target="_blank">spinal cord decompression</a> may prevent or potentially reverse neurologic compromise [<a href="#rid51">51</a>]. Deficient ossification of the superior acetabulum may result in progressive dislocation of the hip joint and erosions of the femoral neck. Joint replacement surgery is possible using a standard prosthesis [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Odontoid hypoplasia</span><span class="headingEndMark"> — </span>Hypoplasia or dysplasia of the odontoid (a tooth- or peg-like projection from the second cervical vertebra) is a characteristic finding in MPS IV A and IV B and is common in the severe forms of MPS I and VII. Hypoplasia is due in part to inadequate ossification, although reossification may occur after cervical fusion. Odontoid hypoplasia can lead to atlantoaxial instability, which can result in subluxation of the first and second cervical vertebrae (C1-C2 subluxation) and high spinal cord compression [<a href="#rid4">4,53,54</a>]. (See <a class="local">'C1-C2 subluxation'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h3">Subluxation and kyphoscoliosis</span><span class="headingEndMark"> — </span>Vertebral subluxation and kyphoscoliosis can occur throughout the spinal column, although they usually occur at points of transition (cervicothoracic, thoracolumbar, and lumbosacral junctions). The causes of kyphoscoliosis include dysplastic vertebral bodies (beaked vertebrae), subluxation (which results in part from ligamentous laxity), and compression or deformation of the vertebral bodies. Subluxation can compromise the cord at any level.</p><p>Patients with Hurler syndrome (MPS I) often develop a gibbus deformity of the lumbar spine, characterized by anterior wedging and posterior displacement of the vertebrae at the peak of the curve  (<a class="graphic graphic_picture graphicRef75426" href="/z/d/graphic/75426.html" rel="external">picture 1</a>), resulting in a beaked appearance on lateral radiographs  (<a class="graphic graphic_diagnosticimage graphicRef52046" href="/z/d/graphic/52046.html" rel="external">image 1</a>) [<a href="#rid55">55</a>]. The causes of gibbus formation include incomplete ossification of the abnormal vertebrae, poor truncal tone, disturbed growth, anterior disc herniation, and weight bearing. Spondylolisthesis (forward slippage of the fifth lumbar vertebra [L5] over the first sacral vertebra [S1]) occurs in the majority of patients with less severe forms of MPS I.</p><p>The goal of treatment is to stabilize the spine with the minimum necessary intervention. Spinal fusion surgery may be required [<a href="#rid56">56,57</a>]. However, MPS patients may not heal well and often have complications from surgical procedures. Thus, fusion surgery should be performed only when necessary. Orthotic bracing may be used early on as a temporizing measure, allowing the patient to grow more before proceeding with definitive surgery.</p><p class="headingAnchor" id="H17"><span class="h2">Genu valgum</span><span class="headingEndMark"> — </span>Abnormalities in the growth plates and epiphyses are caused by glycosaminoglycan (GAG) storage in the chondrocytes. In the knee, storage may lead to inadequate growth in the medial part of the tibial growth plate, causing genu valgum, or knock-knee deformity. This abnormality occurs in the majority of patients with MPS IV A and IV B but also can occur in other types. Severe cases require osteotomy and straightening procedures [<a href="#rid58">58,59</a>]. Early operative intervention while the child is growing includes epiphysiodesis (fusion of the growth plate). (See  <a class="medical medical_review" href="/z/d/html/6290.html" rel="external">"Approach to the child with knock-knees", section on 'Pathologic knock-knees'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Short stature</span><span class="headingEndMark"> — </span>The extensive skeletal abnormalities impair growth and result in short stature. Growth hormone resistance may also play a role in patients with MPS I [<a href="#rid60">60</a>]. Although patients with severe MPS I may have accelerated growth in the first year, height attained is typically less than the fifth percentile. Less severely affected children may reach normal or near-normal heights. Patients with MPS II have accelerated growth in the first three years of life but subsequently have decreased growth velocity [<a href="#rid61">61</a>]. The adolescent growth spurt occurs earlier in boys with MPS II. Enzyme replacement therapy (ERT) may improve growth in patients with MPS II, particularly if therapy is started before 10 years of age [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Joint stiffness and degenerative disease</span><span class="headingEndMark"> — </span>Joint stiffness associated with pain on movement occurs in nearly all MPS patients. The etiology of the stiffness includes inflammatory changes, engorgement of the synovial and other connective tissues of the joint, and abnormalities of the cartilage and epiphyseal bone [<a href="#rid63">63-65</a>]. Pain and decreased movement can lead to development of contractures  (<a class="graphic graphic_picture graphicRef64899" href="/z/d/graphic/64899.html" rel="external">picture 2</a>). This progression may be hastened in some patients by poor neurologic function.</p><p>Physical therapy can improve flexibility of the joints and help maintain function. However, it cannot prevent the inexorable decline in joint mobility. Wheelchairs are often needed for mobility, even in patients who can walk, because of pain and/or limited endurance. Animal studies suggest a possible therapeutic role for tumor necrosis factor (TNF) alpha antagonists, but additional studies are necessary [<a href="#rid63">63</a>].</p><p>Patients can develop painful and debilitating degenerative hip disease due to abnormalities in the femoral epiphyses. The optimal management for hip disease in MPS patients is unclear, and attempts to reach consensus have been challenging due to a poor evidence base and divergent practice [<a href="#rid66">66</a>]. Common approaches focus on exercise recommendations, physical therapy, adequate analgesia, and surgery where possible and probably provide functional benefit. There is anecdotal evidence for an increase in total hip replacements in adolescents and young adults with MPS diseases.</p><p class="headingAnchor" id="H20"><span class="h2">Ligamentous laxity</span><span class="headingEndMark"> — </span>Although lysosomal storage causes some joints to be stiff, GAG accumulation in ligaments can lead to laxity of other joints. This is seen most often in MPS IV A and IV B [<a href="#rid67">67</a>]. Ligamentous laxity contributes to atlantoaxial instability and the development of kyphoscoliosis. (See <a class="local">'Central apnea from cord compression'</a> above and <a class="local">'Odontoid hypoplasia'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h2">Hernias</span><span class="headingEndMark"> — </span>Inguinal and umbilical hernias resulting from connective tissue abnormalities are common, especially in MPS I, II, VI, and VII [<a href="#rid2">2,48,68</a>]. They may occur early on as part of the initial presentation and can become quite large [<a href="#rid69">69</a>]. Hernias can also occur at the incision site following abdominal surgery. Hepatosplenomegaly may contribute to increased intra-abdominal pressure and lead to hernia formation.</p><p>Surgical repair of inguinal hernias may fail and need to be repeated. Hepatosplenomegaly and the weak connective tissues may contribute to poor results. Thus, in some patients, management with trusses is a temporary option that may be preferable to the risk of anesthesia and surgical repair. However, large umbilical hernias that occur in MPS I should be repaired when possible since their size can lead to breakdown of the overlying skin.</p><p class="headingAnchor" id="H22"><span class="h1">NEUROLOGIC COMPLICATIONS</span><span class="headingEndMark"> — </span>Neurologic complications can result from storage in cells in the brain; in supporting structures, such as the meninges or spinal column; or directly in sensory organs, such as the eye. Characteristic findings on cranial magnetic resonance imaging (MRI) include arachnoid cysts, enlarged cisterna magna, cerebellar hypoplasia, encephaloceles, and linear cyst-like structures in the subcortical white matter and corpus callosum [<a href="#rid70">70-76</a>]. These cysts are due to storage in the Virchow-Robin spaces around the blood vessels and are not associated with cognitive defects  (<a class="graphic graphic_diagnosticimage graphicRef74009" href="/z/d/graphic/74009.html" rel="external">image 2</a>) [<a href="#rid71">71,77</a>]. Alterations of myelination may occur. Patients with increased intracranial pressure (ICP) can have significant ventriculomegaly, although some have minimal or no ventricular enlargement associated with transependymal fluid shifts in the periventricular areas.</p><p>Patients initially may be misdiagnosed as having idiopathic developmental delay, autism spectrum disorders, and/or attention deficit hyperactivity disorder [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/6172.html" rel="external">"Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Developmental delay and neurologic decline</span><span class="headingEndMark"> — </span>Developmental delay and progressive decline occur in severe forms of MPS I, II, III, and VII [<a href="#rid2">2,48,79-81</a>]. Patients with MPS IV and VI usually have normal intellectual development. In Hurler syndrome (MPS I), delay that begins during the first year of life is often not appreciated until the second year. In most cases, affected children begin to walk and speak short sentences before reaching a developmental plateau. They then decline slowly so that the average intelligence quotient (IQ) is 50 by age three to four years [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Abnormal behavior</span><span class="headingEndMark"> — </span>Patients with Hurler syndrome (MPS I) tend to be pleasant, good-natured children with excellent behavior during the early stages of the disease but often become unresponsive as the disease progresses to its final stages. In severe Hunter (MPS II) and Sanfilippo (MPS III) syndromes, developmental delay typically is noted at two to six years of age and is accompanied by hyperactive and aggressive behavior [<a href="#rid80">80,83-86</a>]. Patients have short attention spans, do not respond to instructions, and have no sense of danger. The aggressive behavior appears to improve with age as overall function progressively declines, usually reaching a neurologically devastated and unresponsive state in the early teenage years. Abnormal behavior in some patients may be caused by hydrocephalus with increased ICP, although the prevalence of this problem in MPS III is unknown. Patients with MPS II can have meningeal obstruction and high-pressure hydrocephalus, causing severe headaches that may in some cases worsen the behavior problems.</p><p>Management consists primarily of ensuring that the home environment is safe. Attempts to treat the abnormal behavior with medications have been limited by their side effects [<a href="#rid68">68,87</a>]. Medications that are sometimes used include neuroleptics (eg, <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">risperidone</a>, <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">olanzapine</a>), which may cause excessive sedation; benzodiazepines, which may increase secretions and cause respiratory compromise in patients with airway problems, bulbar palsy, and decreased swallowing; tricyclic antidepressants; selective serotonin reuptake inhibitors (eg, <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">fluoxetine</a>), which should be avoided in patients with seizures; and anticonvulsants (eg, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>). <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">Methylphenidate</a> is usually not helpful [<a href="#rid87">87,88</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures may occur in Hunter (MPS II) and Sanfilippo (MPS III) syndromes but are rarely seen in other MPS disorders [<a href="#rid70">70</a>]. Electroencephalographic data in a few MPS patients with seizures demonstrate irregular slow wave activity and typical epileptiform discharges [<a href="#rid70">70,83,89</a>]. Seizures are managed with anticonvulsant medications similar to patients without MPS. (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Sleep disturbance</span><span class="headingEndMark"> — </span>Sleep disturbance is common, especially in Sanfilippo (MPS III) syndrome [<a href="#rid87">87,88</a>]. Sleep becomes progressively fragmented [<a href="#rid90">90</a>], and patients become active around the clock.</p><p>A padded bedroom is usually required to keep the child contained and avoid injury during the night. Restraints are generally not effective. Medications, including melatonin or sedatives, may improve sleep. Melatonin is estimated to be successful in approximately 75 percent of patients within three to four days of use. The authors start with a dose of 2 to 3 mg and increase if necessary after one to two weeks to 4 to 6 mg, with further increases as clinically indicated. Children with MPS frequently require treatment with the maximum dose of 10 mg. Melatonin is used with a strict regimen of sleep time and a darkened bedroom. Benzodiazepines, antihistamines, and <a class="drug drug_pediatric" data-topicid="13143" href="/z/d/drug information/13143.html" rel="external">chloral hydrate</a> are overall reported as less efficacious [<a href="#rid91">91</a>].</p><p>Sleep disturbances contribute to exhaustion of the caretakers. Respite care should be made available for the parents.</p><p class="headingAnchor" id="H27"><span class="h2">Hydrocephalus</span><span class="headingEndMark"> — </span>Communicating hydrocephalus may develop in MPS I, II, III, VI, and VII [<a href="#rid2">2,8,92-95</a>]. In MPS I, II, VI, and VII, the mechanism is engorgement of the arachnoid granulations by storage material, impeding resorption of cerebrospinal fluid (CSF), and increasing ICP  (<a class="graphic graphic_diagnosticimage graphicRef75849" href="/z/d/graphic/75849.html" rel="external">image 3</a>) [<a href="#rid96">96</a>]. In MPS III patients, ventricular enlargement may be due to hydrocephalus but more commonly is due to atrophy in the later stages of the illness. Acute increases in ICP may present with severe headaches, visual disturbances, altered mental status, and rapidly progressive developmental decline [<a href="#rid92">92</a>]. However, the process may be insidious and without typical signs [<a href="#rid48">48,97</a>]. Papilledema is not a reliable indicator and is often not present in patients with increased ICP. Swelling of the optic nerve head is frequently a precursor of optic atrophy, rather than a sign of increased ICP [<a href="#rid48">48,98</a>]. Another diagnostic pitfall is the interpretation of modest ventriculomegaly seen on MRI as cerebral atrophy rather than high-pressure communicating hydrocephalus.</p><p>The diagnosis of hydrocephalus is confirmed by lumbar puncture with measurement of opening pressure. The disorder is usually managed by placement of a ventriculoperitoneal shunt.</p><p class="headingAnchor" id="H28"><span class="h2">Cervical cord compression</span><span class="headingEndMark"> — </span>Compression of the cervical spinal cord can result from pachymeningitis cervicalis or vertebral subluxation.</p><p class="headingAnchor" id="H29"><span class="h3">Pachymeningitis cervicalis</span><span class="headingEndMark"> — </span>Pachymeningitis cervicalis is the progressive thickening and scarring of the meninges around the cervical spinal cord caused by glycosaminoglycan (GAG) storage in MPS  (<a class="graphic graphic_diagnosticimage graphicRef58332 graphicRef72193" href="/z/d/graphic/58332.html" rel="external">image 4A-B</a>). The thickened meninges may form a tight sleeve around the spinal cord that impedes the flow of CSF and progressively compresses the cervical cord. This process may be compounded by a spinal canal that has been narrowed by bone disease. Pachymeningitis cervicalis was originally described in Maroteaux-Lamy syndrome (MPS VI) but has been reported in MPS I, II, and VII [<a href="#rid99">99-101</a>].</p><p>The clinical course is insidious. Patients may complain of fatigue in their legs and gradually have decreased movement and prefer sedentary activities. Occasional "buckling" of the knees may be attributed to a joint problem. Patients typically present to the clinician for evaluation as weakness or sensory loss becomes more evident. The constellation of motor and sensory defects depends upon the extent and location of the compression and may affect breathing or bowel and bladder control.</p><p>Management of this condition is difficult. The pressure can often be relieved by laminectomy with incision and removal of meningeal tissue [<a href="#rid99">99,102-104</a>]. In patients with accompanying subluxation, fusion of the vertebrae is needed. Surgical treatment may be the only option in many cases. However, these procedures have high surgical and anesthesia risks and may not offer significant benefit in some patients. To prevent serious cervical cord accidents in these patients, it is extremely important to assure that the neck is appropriately protected at all times and is not flexed or extended during intubation or surgery. Presurgical conferences to discuss management with the anesthesiologist and surgeon are necessary to assure that the neck is protected during surgical decompression.</p><p class="headingAnchor" id="H30"><span class="h3">C1-C2 subluxation</span><span class="headingEndMark"> — </span>Odontoid dysplasia and ligamentous laxity can result in subluxation of the first cervical vertebra (C1) on the second cervical vertebra (C2) and cause cord compression [<a href="#rid54">54,105-108</a>]. The instability and frequent movement may impair ossification of the odontoid and result in thickened fibrocartilaginous tissue anterior to the cord, causing further compression [<a href="#rid4">4,6,109</a>]. This problem is common in MPS IV A and IV B but also occurs in MPS I, VI, and VII [<a href="#rid4">4,70,110</a>].</p><p>Cord compression due to subluxation is often anterior and predominantly causes motor dysfunction. Onset of motor dysfunction can be insidious, with slowly progressive and nonspecific fatigue followed by decreased activity and preference for sedentary play. If untreated, the cord compression can result in progressive ascending paresis and paralysis. Compression can be visualized with MRI and cord injury confirmed by the presence of abnormal T2-weighted signal in the cord. Somatosensory evoked potentials of the median or posterior tibial nerves have been used to evaluate functional impairment [<a href="#rid111">111</a>].</p><p>Management includes posterior cervical fusion to stabilize the neck and reduce cord compression injury [<a href="#rid4">4,21,104,105</a>]. Concomitant decompression of excess tissue anterior to the cord may be needed. This procedure should be performed early in MPS IV A and IV B to avoid sudden high cord compression and respiratory arrest following a minor fall in those patients with radiologic instability [<a href="#rid4">4,6,112,113</a>]. Surgery should be performed at centers experienced in the management of MPS. To prevent serious cervical cord accidents in these patients, it is extremely important to assure that the neck is appropriately protected at all times and is not flexed or extended during intubation or surgery. Other MPS patients, especially those with MPS I and MPS VII, should be evaluated with annual radiographs in flexion and extension as well as MRI scans. If cervical instability is present, fusion should be performed. (See <a class="local">'Pachymeningitis cervicalis'</a> above.)</p><p class="headingAnchor" id="H31"><span class="h2">Carpal tunnel syndrome</span><span class="headingEndMark"> — </span>Nerve compression disorders, such as carpal tunnel syndrome, resulting from bone disease and soft tissue storage, are common in MPS [<a href="#rid2">2,8,114-118</a>]. The onset of symptoms can be insidious. Specific symptoms of median nerve compression, such as pain, paresthesias, or weakness, occur rarely in affected children, leading to under-recognition of the disorder [<a href="#rid115">115,119-123</a>]. Signs including thenar atrophy, decreased sweating, claw hand deformity, and weakness are more common.</p><p>All MPS patients should be evaluated for carpal tunnel syndrome using standard methods, such as nerve conduction studies. Treatment by carpal tunnel release results in functional improvement [<a href="#rid115">115</a>]. However, additional accumulation of storage material in soft tissues can lead to recurrence. (See  <a class="medical medical_review" href="/z/d/html/5288.html" rel="external">"Carpal tunnel syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6669.html" rel="external">"Surgery for carpal tunnel syndrome"</a>.)</p><p>Entrapment of other peripheral nerves, such as the ulnar nerve, may occur [<a href="#rid124">124,125</a>]. Treatment is similar to patients without MPS. Trigger finger (flexor tendon entrapment of the digit, typically due to thickening of the digit's first annular pulley) is common [<a href="#rid114">114,126</a>].</p><p class="headingAnchor" id="H32"><span class="h2">Diarrhea</span><span class="headingEndMark"> — </span>MPS II and III patients may develop recurrent or chronic diarrhea. The mechanism is thought to be GAG storage in the neurons of the myenteric plexus, leading to abnormal motility [<a href="#rid127">127</a>]. Although motility has not been directly studied, storage in these cells has been demonstrated in biopsies of the intestinal wall [<a href="#rid87">87</a>]. Diarrhea can be improved with medications that decrease bowel motility (eg, <a class="drug drug_pediatric" data-topicid="12561" href="/z/d/drug information/12561.html" rel="external">loperamide</a>) [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H33"><span class="h1">OPHTHALMOLOGIC COMPLICATIONS</span><span class="headingEndMark"> — </span>Vision-impairing ophthalmologic complications of MPS include corneal clouding, glaucoma, optic neuropathy, and degeneration of the retina [<a href="#rid128">128,129</a>]. Corneal clouding is uncommon in MPS II. These complications seem to develop early in the course and often are present at the time of initial diagnosis. Retinopathy may be a later change.</p><p class="headingAnchor" id="H1480417561"><span class="h1">OTOLARYNGOLOGIC COMPLICATIONS</span><span class="headingEndMark"> — </span>Hearing loss is common in all forms of MPS [<a href="#rid130">130</a>]. It is caused by storage of glycosaminoglycans (GAGs) within the oropharynx, dysostosis of the ossicles of the middle ear, and damage to the eighth nerve and may be made worse by frequent ear infections.</p><p class="headingAnchor" id="H1130279684"><span class="h1">DENTAL COMPLICATIONS</span><span class="headingEndMark"> — </span>Unerupted teeth and enamel hypoplasia are common. Many patients present with flattening of the mandibular condyle with decreased mobility of the temporomandibular joint [<a href="#rid131">131</a>].</p><p class="headingAnchor" id="H3955579102"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Additional studies are needed when the diagnosis of MPS disease is made to evaluate for complications:</p><p class="bulletIndent1"><span class="glyph">●</span>An ophthalmologic examination should be performed as part of the initial review and then as needed as determined by the ophthalmologist to assess corneal clouding and glaucoma. Glaucoma is most common in MPS I, II, VI, and VII. (See  <a class="medical medical_review" href="/z/d/html/6272.html" rel="external">"Overview of glaucoma in infants and children"</a> and <a class="local">'Ophthalmologic complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cardiac evaluation, including electrocardiogram (ECG) and echocardiography, should be performed at the time of diagnosis and then annually to assess valvular disease, cardiomyopathy, cor pulmonale, and heart failure [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive neurologic examination is done at presentation and then annually or when new symptoms occur to detect carpal tunnel syndrome, spinal cord compression, or communicating hydrocephalus. These conditions can be further evaluated with electromyography, somatosensory evoked potentials, and lumbar puncture with measurement of opening pressure. Neuroimaging should be performed if hydrocephalus is suspected and in patients with developmental delay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiographic studies of the neck in flexion and extension (plain films) should be obtained to assess cervical instability and magnetic resonance imaging (MRI) of the craniocervical junction for compression. These studies are obtained annually initially, but the frequency can be reduced in those without significant abnormalities. Plain films may not be required if MRI in flexion and extension is possible. Evaluation of the spine for vertebral slippage and kyphoscoliosis should be performed annually.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have breathing problems at night or daytime somnolence should have oximetry or polysomnography to evaluate obstructive sleep apnea [<a href="#rid132">132</a>]. (See  <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hearing should be tested annually, or more frequently if there is a clinical change, in all patients with MPS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orthopedic evaluation should be performed every 6 to 12 months, depending upon disease severity, to monitor patients for hip and other joint disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dental evaluation should be performed every 6 to 12 months.</p><p></p><p class="headingAnchor" id="H3744207102"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120240.html" rel="external">"Society guideline links: Mucopolysaccharidoses"</a>.)</p><p class="headingAnchor" id="H909199609"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The mucopolysaccharidoses (MPS) are lysosomal storage disorders that are differentiated by their clinical features and age of presentation  (<a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">table 1</a>). These disorders can affect many different systems, including the respiratory, cardiovascular, skeletal, and neurologic systems  (<a class="graphic graphic_table graphicRef120535" href="/z/d/graphic/120535.html" rel="external">table 2</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory complications of MPS may include central apnea, airway obstruction, sleep apnea, and frequent or chronic sinopulmonary infections or otitis media. (See <a class="local">'Respiratory complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac complications of MPS may include cardiomyopathy, endocardial fibroelastosis, valvular disease, vascular disease, and pulmonary hypertension. (See <a class="local">'Cardiac complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal and connective tissue complications of MPS may include dysostosis multiplex (the constellation of characteristic bony abnormalities)  (<a class="graphic graphic_diagnosticimage graphicRef75624" href="/z/d/graphic/75624.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef52046" href="/z/d/graphic/52046.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef50673" href="/z/d/graphic/50673.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef51207" href="/z/d/graphic/51207.html" rel="external">image 7</a> and <a class="graphic graphic_diagnosticimage graphicRef63875" href="/z/d/graphic/63875.html" rel="external">image 8</a>), spine abnormalities, hip dysplasia, genu valgum (knock knees), short stature, joint stiffness, ligamentous laxity, and inguinal and umbilical hernias. (See <a class="local">'Skeletal and connective tissue complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic complications of MPS may include developmental delay or neurologic decline, abnormal behavior, seizures (in Hunter [MPS II] and Sanfilippo [MPS III] syndromes), sleep disturbance, hydrocephalus, cervical cord compression, carpal tunnel syndrome, and diarrhea (thought to be related to abnormal motility). (See <a class="local">'Neurologic complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmologic complications of MPS may include corneal clouding, glaucoma, optic neuropathy, and degeneration of the retina. (See <a class="local">'Ophthalmologic complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MPS should also undergo periodic evaluation for (see <a class="local">'Monitoring'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Corneal clouding  (<a class="graphic graphic_picture graphicRef52924" href="/z/d/graphic/52924.html" rel="external">picture 3</a>) and glaucoma</p><p class="bulletIndent2"><span class="glyph">•</span>Valvular disease, cardiomyopathy, cor pulmonale, and heart failure</p><p class="bulletIndent2"><span class="glyph">•</span>Carpal tunnel syndrome, spinal cord compression  (<a class="graphic graphic_diagnosticimage graphicRef58332" href="/z/d/graphic/58332.html" rel="external">image 4A</a> and <a class="graphic graphic_diagnosticimage graphicRef72193" href="/z/d/graphic/72193.html" rel="external">image 4B</a>), communicating hydrocephalus</p><p class="bulletIndent2"><span class="glyph">•</span>Cervical instability, vertebral slippage, and kyphoscoliosis  (<a class="graphic graphic_picture graphicRef81903" href="/z/d/graphic/81903.html" rel="external">picture 4</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Organomegaly</p><p class="bulletIndent2"><span class="glyph">•</span>Obstructive sleep apnea</p><p class="bulletIndent2"><span class="glyph">•</span>Hearing</p><p class="bulletIndent2"><span class="glyph">•</span>Hip dysplasia and other orthopedic complications</p><p></p><p class="headingAnchor" id="H141167719"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ed Wraith, MD; Emil Kakkis, MD, PhD; Robert Wynn, MD, MRCP, FRCPath; and Simon Jones, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore) 1988; 67:209.</a></li><li><a class="nounderline abstract_t">Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167:267.</a></li><li><a class="nounderline abstract_t">Gönüldaş B, Yılmaz T, Sivri HS, et al. Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway. Int J Pediatr Otorhinolaryngol 2014; 78:944.</a></li><li><a class="nounderline abstract_t">Stevens JM, Kendall BE, Crockard HA, Ransford A. The odontoid process in Morquio-Brailsford's disease. The effects of occipitocervical fusion. J Bone Joint Surg Br 1991; 73:851.</a></li><li><a class="nounderline abstract_t">Jones AE, Croley TF. Morquio syndrome and anesthesia. Anesthesiology 1979; 51:261.</a></li><li><a class="nounderline abstract_t">Ashraf J, Crockard HA, Ransford AO, Stevens JM. Transoral decompression and posterior stabilisation in Morquio's disease. Arch Dis Child 1991; 66:1318.</a></li><li><a class="nounderline abstract_t">Hughes DG, Chadderton RD, Cowie RA, et al. MRI of the brain and craniocervical junction in Morquio's disease. Neuroradiology 1997; 39:381.</a></li><li><a class="nounderline abstract_t">Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120:405.</a></li><li><a class="nounderline abstract_t">Yeung AH, Cowan MJ, Horn B, Rosbe KW. Airway management in children with mucopolysaccharidoses. Arch Otolaryngol Head Neck Surg 2009; 135:73.</a></li><li><a class="nounderline abstract_t">Belani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993; 28:403.</a></li><li><a class="nounderline abstract_t">Brama I, Gay I, Feinmesser R, Springer C. Upper airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 1986; 11:229.</a></li><li><a class="nounderline abstract_t">Simonetti GD, Casaulta C, Vuissoz JM, et al. Recurrent unexplained episodes of facial cyanosis and shortness of breath in Hunter disease. J Pediatr 2009; 155:144, 144.e1.</a></li><li><a class="nounderline abstract_t">Bredenkamp JK, Smith ME, Dudley JP, et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Laryngol 1992; 101:472.</a></li><li><a class="nounderline abstract_t">Leighton SE, Papsin B, Vellodi A, et al. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2001; 58:127.</a></li><li><a class="nounderline abstract_t">Morehead JM, Parsons DS. Tracheobronchomalacia in Hunter's syndrome. Int J Pediatr Otorhinolaryngol 1993; 26:255.</a></li><li><a class="nounderline abstract_t">Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 1994; 49:1078.</a></li><li><a class="nounderline abstract_t">Walker PP, Rose E, Williams JG. Upper airways abnormalities and tracheal problems in Morquio's disease. Thorax 2003; 58:458.</a></li><li><a class="nounderline abstract_t">Ruckenstein MJ, Macdonald RE, Clarke JT, Forte V. The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review. J Otolaryngol 1991; 20:177.</a></li><li><a class="nounderline abstract_t">Baines D, Keneally J. Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital. Anaesth Intensive Care 1983; 11:198.</a></li><li><a class="nounderline abstract_t">Kempthorne PM, Brown TC. Anaesthesia and the mucopolysaccharidoses: a survey of techniques and problems. Anaesth Intensive Care 1983; 11:203.</a></li><li><a class="nounderline abstract_t">Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care 1996; 24:459.</a></li><li><a class="nounderline abstract_t">Sjøgren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand 1987; 31:214.</a></li><li><a class="nounderline abstract_t">Suzuki M, Tsukagoshi M, Ashizawa N, Fukunaga A. [Anesthetic management of mucopolysaccharidosis]. Masui 1976; 25:977.</a></li><li><a class="nounderline abstract_t">Walker R, Belani KG, Braunlin EA, et al. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36:211.</a></li><li><a class="nounderline abstract_t">Linstedt U, Maier C, Joehnk H, Stephani U. Threatening spinal cord compression during anesthesia in a child with mucopolysaccharidosis VI. Anesthesiology 1994; 80:227.</a></li><li><a class="nounderline abstract_t">Tobias JD. Anesthetic care for the child with Morquio syndrome: general versus regional anesthesia. J Clin Anesth 1999; 11:242.</a></li><li><a class="nounderline abstract_t">Vas L, Naregal F. Failed epidural anaesthesia in a patient with Hurler's disease. Paediatr Anaesth 2000; 10:95.</a></li><li><a class="nounderline abstract_t">Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth 1997; 7:421.</a></li><li><a class="nounderline abstract_t">Daly TM, Lorenz RG, Sands MS. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr Res 2000; 47:757.</a></li><li><a class="nounderline abstract_t">Torres LC, Soares DC, Kulikowski LD, et al. NK and B cell deficiency in a MPS type II family with novel mutation in the IDS gene. Clin Immunol 2014; 154:100.</a></li><li><a class="nounderline abstract_t">Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36:201.</a></li><li><a class="nounderline abstract_t">Lin SP, Shih SC, Chuang CK, et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment. Pediatr Pulmonol 2014; 49:277.</a></li><li><a class="nounderline abstract_t">Wooten WI 3rd, Muenzer J, Vaughn BV, Muhlebach MS. Relationship of sleep to pulmonary function in mucopolysaccharidosis II. J Pediatr 2013; 162:1210.</a></li><li><a class="nounderline abstract_t">Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 2011; 34:1183.</a></li><li><a class="nounderline abstract_t">Donaldson MD, Pennock CA, Berry PJ, et al. Hurler syndrome with cardiomyopathy in infancy. J Pediatr 1989; 114:430.</a></li><li><a class="nounderline abstract_t">Hayflick S, Rowe S, Kavanaugh-McHugh A, et al. Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI. J Pediatr 1992; 120:269.</a></li><li><a class="nounderline abstract_t">Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol 1983; 4:61.</a></li><li><a class="nounderline abstract_t">Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients. Eur J Pediatr 1998; 157:534.</a></li><li><a class="nounderline abstract_t">Wippermann CF, Beck M, Schranz D, et al. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995; 154:98.</a></li><li><a class="nounderline abstract_t">Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990; 27:94.</a></li><li><a class="nounderline abstract_t">Masuda H, Morishita Y, Taira A, Kuriyama M. Aortic stenosis associated with Scheie's syndrome. Report of successful valve replacement. Chest 1993; 103:968.</a></li><li><a class="nounderline abstract_t">Butman SM, Karl L, Copeland JG. Combined aortic and mitral valve replacement in an adult with Scheie's disease. Chest 1989; 96:209.</a></li><li><a class="nounderline abstract_t">Tan CT, Schaff HV, Miller FA Jr, et al. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation 1992; 85:188.</a></li><li><a class="nounderline abstract_t">Taylor DB, Blaser SI, Burrows PE, et al. Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings. AJR Am J Roentgenol 1991; 157:819.</a></li><li><a class="nounderline abstract_t">Braunlin EA, Hunter DW, Krivit W, et al. Evaluation of coronary artery disease in the Hurler syndrome by angiography. Am J Cardiol 1992; 69:1487.</a></li><li><a class="nounderline abstract_t">Brosius FC 3rd, Roberts WC. Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 1981; 47:649.</a></li><li><a class="nounderline abstract_t">Braunlin E, Wang R. Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs. Heart 2016; 102:1257.</a></li><li class="breakAll">Neufeld EF, Muenzer J. The metabolic and molecular bases of inherited disease, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.3421.</li><li><a class="nounderline abstract_t">Langer LO Jr, Carey LS. The roentgenographic features of the KS mucopolysaccharidosis of Morquio (Morquio-Brailsford's disease). Am J Roentgenol Radium Ther Nucl Med 1966; 97:1.</a></li><li><a class="nounderline abstract_t">Abelin Genevois K, Garin C, Solla F, et al. Surgical management of thoracolumbar kyphosis in mucopolysaccharidosis type 1 in a reference center. J Inherit Metab Dis 2014; 37:69.</a></li><li><a class="nounderline abstract_t">Remondino RG, Tello CA, Noel M, et al. Clinical Manifestations and Surgical Management of Spinal Lesions in Patients With Mucopolysaccharidosis: A Report of 52 Cases. Spine Deform 2019; 7:298.</a></li><li><a class="nounderline abstract_t">Tassinari E, Boriani L, Traina F, et al. Bilateral total hip arthroplasty in Morquio-Brailsford's syndrome: a report of two cases. Chir Organi Mov 2008; 92:123.</a></li><li><a class="nounderline abstract_t">Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia. Clin Genet 1988; 33:126.</a></li><li><a class="nounderline abstract_t">Thomas SL, Childress MH, Quinton B. Hypoplasia of the odontoid with atlanto-axial subluxation in Hurler's syndrome. Pediatr Radiol 1985; 15:353.</a></li><li><a class="nounderline abstract_t">Levin TL, Berdon WE, Lachman RS, et al. Lumbar gibbus in storage diseases and bone dysplasias. Pediatr Radiol 1997; 27:289.</a></li><li><a class="nounderline abstract_t">Roberts SB, Dryden R, Tsirikos AI. Thoracolumbar kyphosis in patients with mucopolysaccharidoses: clinical outcomes and predictive radiographic factors for progression of deformity. Bone Joint J 2016; 98-B:229.</a></li><li><a class="nounderline abstract_t">Bekmez S, Demirkiran HG, Dede O, et al. Surgical Management of Progressive Thoracolumbar Kyphosis in Mucopolysaccharidosis: Is a Posterior-only Approach Safe and Effective? J Pediatr Orthop 2018; 38:354.</a></li><li><a class="nounderline abstract_t">Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996; 19:357.</a></li><li><a class="nounderline abstract_t">Odunusi E, Peters C, Krivit W, Ogilvie J. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop 1999; 19:270.</a></li><li><a class="nounderline abstract_t">Gardner CJ, Robinson N, Meadows T, et al. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J Inherit Metab Dis 2011; 34:489.</a></li><li><a class="nounderline abstract_t">Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 2011; 100:456.</a></li><li><a class="nounderline abstract_t">Schulze-Frenking G, Jones SA, Roberts J, et al. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011; 34:203.</a></li><li><a class="nounderline abstract_t">Simonaro CM, Ge Y, Eliyahu E, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010; 107:222.</a></li><li><a class="nounderline abstract_t">Simonaro CM, D'Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008; 172:112.</a></li><li><a class="nounderline abstract_t">Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005; 57:701.</a></li><li><a class="nounderline abstract_t">Langereis EJ, Borgo A, Crushell E, et al. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 2013; 8:155.</a></li><li><a class="nounderline abstract_t">Kopits SE. Orthopedic complications of dwarfism. Clin Orthop Relat Res 1976; :153.</a></li><li><a class="nounderline abstract_t">Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995; 72:263.</a></li><li><a class="nounderline abstract_t">Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 1995; 84:337.</a></li><li class="breakAll">Kakkis ED, Neufeld EF. The mucopolysaccharidoses. In: Principles of child neurology, Berg BO (Ed), McGraw-Hill, New York 1996. p.1141.</li><li><a class="nounderline abstract_t">Gabrielli O, Salvolini U, Maricotti M, et al. Cerebral MRI in two brothers with mucopolysaccharidosis type I and different clinical phenotypes. Neuroradiology 1992; 34:313.</a></li><li><a class="nounderline abstract_t">Shimoda-Matsubayashi S, Kuru Y, Sumie H, et al. MRI findings in the mild type of mucopolysaccharidosis II (Hunter's syndrome). Neuroradiology 1990; 32:328.</a></li><li><a class="nounderline abstract_t">Taccone A, Tortori Donati P, Marzoli A, et al. Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol 1993; 23:349.</a></li><li><a class="nounderline abstract_t">Afifi AK, Sato Y, Waziri MH, Bell WE. Computed tomography and magnetic resonance imaging of the brain in Hurler's disease. J Child Neurol 1990; 5:235.</a></li><li><a class="nounderline abstract_t">Johnson MA, Desai S, Hugh-Jones K, Starer F. Magnetic resonance imaging of the brain in Hurler syndrome. AJNR Am J Neuroradiol 1984; 5:816.</a></li><li><a class="nounderline abstract_t">Parsons VJ, Hughes DG, Wraith JE. Magnetic resonance imaging of the brain, neck and cervical spine in mild Hunter's syndrome (mucopolysaccharidoses type II). Clin Radiol 1996; 51:719.</a></li><li><a class="nounderline abstract_t">Wassman ER, Johnson K, Shapiro LJ, et al. Postmortem findings in the Hurler-Scheie syndrome (mucopolysaccharidosis I-H/S). Birth Defects Orig Artic Ser 1982; 18:13.</a></li><li><a class="nounderline abstract_t">Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102:462.</a></li><li><a class="nounderline abstract_t">Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998; 2:250.</a></li><li><a class="nounderline abstract_t">Nidiffer FD, Kelly TE. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J Ment Defic Res 1983; 27 (Pt 3):185.</a></li><li><a class="nounderline abstract_t">Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: A review. Mol Genet Metab 2021; 133:8.</a></li><li><a class="nounderline abstract_t">Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18:413.</a></li><li><a class="nounderline abstract_t">Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983; 25:481.</a></li><li><a class="nounderline abstract_t">van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981; 20:152.</a></li><li><a class="nounderline abstract_t">Wraith JE, Danks DM, Rogers JG. Mild Sanfilippo syndrome: a further cause of hyperactivity and behavioural disturbance. Med J Aust 1987; 147:450.</a></li><li><a class="nounderline abstract_t">Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995; 73:77.</a></li><li><a class="nounderline abstract_t">Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child 1993; 69:403.</a></li><li><a class="nounderline abstract_t">Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol 1996; 38:538.</a></li><li><a class="nounderline abstract_t">Kriel RL, Hauser WA, Sung JH, Posalaky Z. Neuroanatomical and electroencephalographic correlations in Sanfilippo syndrome, type A. Arch Neurol 1978; 35:838.</a></li><li><a class="nounderline abstract_t">Mumford RA, Mahon LV, Jones S, et al. Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome). J Neurodev Disord 2015; 7:31.</a></li><li><a class="nounderline abstract_t">Fraser J, Wraith JE, Delatycki MB. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet 2002; 62:418.</a></li><li><a class="nounderline abstract_t">Shinnar S, Singer HS, Valle D. Acute hydrocephalus Hurler's syndrome. Am J Dis Child 1982; 136:556.</a></li><li><a class="nounderline abstract_t">Van Aerde J, Campbell A. Hydrocephalus and shunt placement. Am J Dis Child 1983; 137:187.</a></li><li><a class="nounderline abstract_t">Sheridan M, Johnston I. Hydrocephalus and pseudotumour cerebri in the mucopolysaccharidoses. Childs Nerv Syst 1994; 10:148.</a></li><li><a class="nounderline abstract_t">Goldberg MF, Scott CI, McKusick VA. Hydrocephalus and papilledema in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Am J Ophthalmol 1970; 69:969.</a></li><li><a class="nounderline abstract_t">van Aerde J, Plets C, Van der Hauwaert L. Hydrocephalus in Hunter Syndrome. Acta Paediatr Belg 1981; 34:93.</a></li><li><a class="nounderline abstract_t">Muenzer J. Mucopolysaccharidoses. Adv Pediatr 1986; 33:269.</a></li><li><a class="nounderline abstract_t">Collins ML, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 1990; 97:1445.</a></li><li><a class="nounderline abstract_t">Kaufman HH, Rosenberg HS, Scott CI, et al. Cervical myelopathy due to dural compression in mucopolysaccharidosis. Surg Neurol 1982; 17:404.</a></li><li><a class="nounderline abstract_t">Paulson GW, Meagher JN, Burkhart J. Spinal pachymeningitis secondary to mucopolysaccharidosis. Case report. J Neurosurg 1974; 41:618.</a></li><li><a class="nounderline abstract_t">Kachur E, Del Maestro R. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery 2000; 47:223.</a></li><li><a class="nounderline abstract_t">Young R, Kleinman G, Ojemann RG, et al. Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings. Ann Neurol 1980; 8:336.</a></li><li><a class="nounderline abstract_t">Banna M, Hollenberg R. Compressive meningeal hypertrophy in mucopolysaccharidosis. AJNR Am J Neuroradiol 1987; 8:385.</a></li><li><a class="nounderline abstract_t">O'Brien DP, Cowie RA, Wraith JE. Cervical decompression in mild mucopolysaccharidosis type II (Hunter syndrome). Childs Nerv Syst 1997; 13:87.</a></li><li><a class="nounderline abstract_t">Instability of the upper cervical spine. Skeletal Dysplasia Group. Arch Dis Child 1989; 64:283.</a></li><li><a class="nounderline abstract_t">Brill CB, Rose JS, Godmilow L, et al. Spastic quadriparesis due to C1-C2 subluxation in Hurler syndrome. J Pediatr 1978; 92:441.</a></li><li><a class="nounderline abstract_t">Pizzutillo PD, Osterkamp JA, Scott CI Jr, Lee MS. Atlantoaxial instability in mucopolysaccharidosis type VII. J Pediatr Orthop 1989; 9:76.</a></li><li><a class="nounderline abstract_t">Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996; 78:938.</a></li><li><a class="nounderline abstract_t">Ransford AO, Crockard HA, Stevens JM, Modaghegh S. Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience. J Bone Joint Surg Br 1996; 78:307.</a></li><li><a class="nounderline abstract_t">Lipson SJ. Dysplasia of the odontoid process in Morquio's syndrome causing quadriparesis. J Bone Joint Surg Am 1977; 59:340.</a></li><li><a class="nounderline abstract_t">Boor R, Miebach E, Brühl K, Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics 2000; 31:122.</a></li><li><a class="nounderline abstract_t">Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop (Belle Mead NJ) 1997; 26:533.</a></li><li><a class="nounderline abstract_t">Gulati MS, Agin MA. Morquio syndrome: a rehabilitation perspective. J Spinal Cord Med 1996; 19:12.</a></li><li><a class="nounderline abstract_t">Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg Am 1998; 23:236.</a></li><li><a class="nounderline abstract_t">Haddad FS, Jones DH, Vellodi A, et al. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br 1997; 79:576.</a></li><li><a class="nounderline abstract_t">Gschwind C, Tonkin MA. Carpal tunnel syndrome in children with mucopolysaccharidosis and related disorders. J Hand Surg Am 1992; 17:44.</a></li><li><a class="nounderline abstract_t">Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child 1990; 65:962.</a></li><li><a class="nounderline abstract_t">Yuen A, Dowling G, Johnstone B, et al. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol 2007; 22:260.</a></li><li><a class="nounderline abstract_t">Norman-Taylor F, Fixsen JA, Sharrard WJ. Hunter's syndrome as a cause of childhood carpal tunnel syndrome: a report of three cases. J Pediatr Orthop B 1995; 4:106.</a></li><li><a class="nounderline abstract_t">Bona I, Vial C, Brunet P, et al. Carpal tunnel syndrome in Mucopolysaccharidoses. A report of four cases in child. Electromyogr Clin Neurophysiol 1994; 34:471.</a></li><li><a class="nounderline abstract_t">Cruz Martínez A, Arpa J. Carpal tunnel syndrome in childhood: study of 6 cases. Electroencephalogr Clin Neurophysiol 1998; 109:304.</a></li><li><a class="nounderline abstract_t">MacDougal B, Weeks PM, Wray RC Jr. Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases. Plast Reconstr Surg 1977; 59:260.</a></li><li><a class="nounderline abstract_t">Pronicka E, Tylki-Szymanska A, Kwast O, et al. Carpal tunnel syndrome in children with mucopolysaccharidoses: needs for surgical tendons and median nerve release. J Ment Defic Res 1988; 32 ( Pt 1):79.</a></li><li><a class="nounderline abstract_t">Karpati G, Carpenter S, Eisen AA, et al. Multiple peripheral nerve entrapments. An unusual phenotypical variant of the Hunter syndrome (mucopolysaccharidosis II) in a family. Arch Neurol 1974; 31:418.</a></li><li><a class="nounderline abstract_t">Swift TR, McDonald TF. Peripheral nerve involvement in Hunter syndrome (mucopolysaccharidosis II). Arch Neurol 1976; 33:845.</a></li><li><a class="nounderline abstract_t">Haddad FS, Hill RA, Jones DH. Triggering in the mucopolysaccharidoses. J Pediatr Orthop B 1998; 7:138.</a></li><li><a class="nounderline abstract_t">Elsner B. Ultrastructure of the rectal wall in Hunter's syndrome. Gastroenterology 1970; 58:856.</a></li><li><a class="nounderline abstract_t">Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008; 38:543.</a></li><li><a class="nounderline abstract_t">Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol 2015; 9:1633.</a></li><li><a class="nounderline abstract_t">Wolfberg J, Chintalapati K, Tomatsu S, Nagao K. Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions. Diagnostics (Basel) 2020; 10.</a></li><li><a class="nounderline abstract_t">de Almeida-Barros RQ, de Medeiros PFV, de Almeida Azevedo MQ, et al. Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study. Clin Oral Investig 2018; 22:201.</a></li><li><a class="nounderline abstract_t">Lin HY, Chen MR, Lin CC, et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol 2010; 45:1205.</a></li></ol></div><div id="topicVersionRevision">Topic 2932 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134589" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Respiratory complications of mucopolysaccharide storage disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18038146" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731921" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1910048" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The odontoid process in Morquio-Brailsford's disease. The effects of occipitocervical fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/112883" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Morquio syndrome and anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1755646" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transoral decompression and posterior stabilisation in Morquio's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189888" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : MRI of the brain and craniocervical junction in Morquio's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671068" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management guidelines for mucopolysaccharidosis VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153310" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Airway management in children with mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8468655" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3095256" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Upper airway obstruction in Hunter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19559302" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent unexplained episodes of facial cyanosis and shortness of breath in Hunter disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1610064" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Otolaryngologic manifestations of the mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11278021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disordered breathing during sleep in patients with mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509249" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tracheobronchomalacia in Hunter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864325" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anaesthesia and mucopolysaccharidoses. A review of airway problems in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728175" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Upper airways abnormalities and tracheal problems in Morquio's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1908026" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6412587" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6412588" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anaesthesia and the mucopolysaccharidoses: a survey of techniques and problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862643" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anaesthesia for children with mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3107330" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mucopolysaccharidoses and anaesthetic risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/825664" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : [Anesthetic management of mucopolysaccharidosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197104" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anaesthesia and airway management in mucopolysaccharidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8291716" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Threatening spinal cord compression during anesthesia in a child with mucopolysaccharidosis VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10434222" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anesthetic care for the child with Morquio syndrome: general versus regional anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632918" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Failed epidural anaesthesia in a patient with Hurler's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308068" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10832733" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Abnormal immune function in vivo in a murine model of lysosomal storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038527" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : NK and B cell deficiency in a MPS type II family with novel mutation in the IDS gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23151682" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Respiratory and sleep disorders in mucopolysaccharidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401495" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23305961" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Relationship of sleep to pulmonary function in mucopolysaccharidosis II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21744090" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2493520" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hurler syndrome with cardiomyopathy in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735826" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405371" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9686810" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7720756" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2108248" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiovascular studies in the mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8449111" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Aortic stenosis associated with Scheie's syndrome. Report of successful valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500310" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combined aortic and mitral valve replacement in an adult with Scheie's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728449" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Valvular heart disease in four patients with Maroteaux-Lamy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1909834" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1590242" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of coronary artery disease in the Hurler syndrome by angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6781324" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102649" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102649" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4223084" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The roentgenographic features of the KS mucopolysaccharidosis of Morquio (Morquio-Brailsford's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813121" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Surgical management of thoracolumbar kyphosis in mucopolysaccharidosis type 1 in a reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660225" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical Manifestations and Surgical Management of Spinal Lesions in Patients With Mucopolysaccharidosis: A Report of 52 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18488165" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bilateral total hip arthroplasty in Morquio-Brailsford's syndrome: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129223" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3929221" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypoplasia of the odontoid with atlanto-axial subluxation in Hurler's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9094231" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lumbar gibbus in storage diseases and bone dysplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26850429" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Thoracolumbar kyphosis in patients with mucopolysaccharidoses: clinical outcomes and predictive radiographic factors for progression of deformity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27403916" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Surgical Management of Progressive Thoracolumbar Kyphosis in Mucopolysaccharidosis: Is a Posterior-only Approach Safe and Effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803780" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10088702" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21253827" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20950410" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978944" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20018674" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079441" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746260" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24088413" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/816586" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Orthopedic complications of dwarfism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741581" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The mucopolysaccharidoses: a clinical review and guide to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780260" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The presenting features of mucopolysaccharidosis type IH (Hurler syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780260" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The presenting features of mucopolysaccharidosis type IH (Hurler syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528441" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cerebral MRI in two brothers with mucopolysaccharidosis type I and different clinical phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2122274" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : MRI findings in the mild type of mucopolysaccharidosis II (Hunter's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8233683" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2118924" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Computed tomography and magnetic resonance imaging of the brain in Hurler's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6437186" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Magnetic resonance imaging of the brain in Hurler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8893643" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Magnetic resonance imaging of the brain, neck and cervical spine in mild Hunter's syndrome (mucopolysaccharidoses type II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6814547" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Postmortem findings in the Hurler-Scheie syndrome (mucopolysaccharidosis I-H/S).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23336697" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084724" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6415286" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33741271" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The natural history of neurocognition in MPS disorders: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7494400" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6413286" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6796310" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3118155" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mild Sanfilippo syndrome: a further cause of hyperactivity and behavioural disturbance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639557" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Behaviour in mucopolysaccharide disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215557" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of mucopolysaccharidosis type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647333" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sleep problems in children with Sanfilippo syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/214061" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neuroanatomical and electroencephalographic correlations in Sanfilippo syndrome, type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388955" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12431260" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807082" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Acute hydrocephalus Hurler's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6401388" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hydrocephalus and shunt placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044807" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hydrocephalus and pseudotumour cerebri in the mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4246483" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hydrocephalus and papilledema in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801919" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Hydrocephalus in Hunter Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3099554" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123975" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6810485" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cervical myelopathy due to dural compression in mucopolysaccharidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4278439" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Spinal pachymeningitis secondary to mucopolysaccharidosis. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917366" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776877" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3105300" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Compressive meningeal hypertrophy in mucopolysaccharidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105743" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cervical decompression in mild mucopolysaccharidosis type II (Hunter syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2494953" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Instability of the upper cervical spine. Skeletal Dysplasia Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/416190" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Spastic quadriparesis due to C1-C2 subluxation in Hurler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492542" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Atlantoaxial instability in mucopolysaccharidosis type VII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951011" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Spinal problems in mucopolysaccharidosis I (Hurler syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8666648" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/403192" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Dysplasia of the odontoid process in Morquio's syndrome causing quadriparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963098" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267552" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A review of Morquio syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8673508" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Morquio syndrome: a rehabilitation perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9556262" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250742" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538111" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Carpal tunnel syndrome in children with mucopolysaccharidosis and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2121106" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621494" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Carpal tunnel syndrome in children with mucopolysaccaridoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7719824" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hunter's syndrome as a cause of childhood carpal tunnel syndrome: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882890" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Carpal tunnel syndrome in Mucopolysaccharidoses. A report of four cases in child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751292" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Carpal tunnel syndrome in childhood: study of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/402008" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129563" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Carpal tunnel syndrome in children with mucopolysaccharidoses: needs for surgical tendons and median nerve release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4280298" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Multiple peripheral nerve entrapments. An unusual phenotypical variant of the Hunter syndrome (mucopolysaccharidosis II) in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/187158" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Peripheral nerve involvement in Hunter syndrome (mucopolysaccharidosis II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597590" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Triggering in the mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4246486" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Ultrastructure of the rectal wall in Hunter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299822" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26379420" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759694" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28315965" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20717914" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Polysomnographic characteristics in patients with mucopolysaccharidoses.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
